Epidemiology of transmitted drug resistance in chronically HIV-infected patients in Germany: The RESINA study 2001-2009

Intervirology

Volumn 55, Issue 2, 2012, Pages 154-159

  Oette, Mark ^a   Reuter, Stefan ^d   Kaiser, Rolf ^b   Lengauer, Thomas ^e   Fätkenheuer, Gerd ^c   Knechten, Heribert ^f   Hower, Martin ^g   Pfister, Herbert ^b   Häussinger, Dieter ^d  

^a Augustinerinnen Hospital   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^d UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^e MPI for Bioinfomatics   (Germany)

^f Private Practice   (Germany)

^g KLINIKUM DORTMUND   (Germany)

Author keywords

Highly active antiretroviral therapy; Primary drug resistance; Resistance prevalence

Indexed keywords

NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DISEASE TRANSMISSION; FEMALE; GENE MUTATION; GENETIC SCREENING; GENOTYPE; GERMANY; HEALTH CARE SURVEY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; SEXUALLY TRANSMITTED DISEASE; VIRUS LOAD; VIRUS STRAIN;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; GERMANY; HIV INFECTIONS; HIV-1; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MOLECULAR TYPING; PREVALENCE; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84856479237     PISSN: 03005526     EISSN: 14230100     Source Type: Journal    
DOI: 10.1159/000332015     Document Type: Article

References (32)

1. Palella FJ Jr, Armon C, Buchacz K, Cole SR, Chmiel JS, Novak RM, Wood K, Moorman AC, Brooks JT, HOPS (HIV Outpatient Study) Investigators: The association of HIV susceptibility testing with survival among HIV-infected patients receiving antiretroviral therapy: a cohort study. Ann Intern Med 2009;151:73-84.
2. Bannister WP, Cozzi-Lepri A, Clotet B, Mocroft A, Kjaer J, Reiss P, von Wyl V, Lazzarin A, Katlama C, Phillips AN, Ruiz L, Lundgren J-grave, EuroSI-graveA Study Group: Transmitted drug resistant HIV-1 and association with virologic and C-grave4 cell count response to combination antiretroviral therapy in the EuroSI-graveA Study. J Acquir Immune Defic Syndr 2008;48:324-333.
3. Bartmeyer B, Kuecherer C, Houareau C, Werning J, Keeren K, Somogyi S, Kollan C, Jessen H, Dupke S, Hamouda O, German HIV-1 Seroconverter Study Group: Prevalence of transmitted drug resistance and impact of transmitted resistance on treatment success in the German HIV-1 Seroconverter Cohort. PLoS One 2010;5:e12718.
4. Bracciale L, Colafigli M, Zazzi M, Corsi P, Meraviglia P, Micheli V, Maserati R, Gianotti N, Penco G, Setti M, Di Giambenedetto S, Butini L, Vivarelli A, Trezzi M, De Luca A: Prevalence of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy: evolution over 12 years and predictors. J Antimicrob Chemother 2009;64:607-615.
5. Chaix ML, Descamps D, Wirden M, Bocket L, Delaugerre C, Tamalet C, Schneider V, Izopet J, Masquelier B, Rouzioux C, Meyer L, Costagliola D, ANRS AC11 Resistance Group, Cohort PRIMO ANRS CO 6, FH-graveH ANRS CO4 Study Groups: Stable frequency of HIV-1 transmitted drug resistance in patients at the time of primary infection over 1996-2006 in France. AI-graveS 2009;23:717-724.
6. Descamps D, Chaix ML, Montes B, Pakianather S, Charpentier C, Storto A, Barin F, Dos Santos G, Krivine A, Delaugerre C, Izopet J, Marcelin AG, Maillard A, Morand-Joubert L, Pallier C, Plantier JC, Tamalet C, Cottalorda J, Desbois D, Calvez V, Brun-Vezinet F, Masquelier B, Costagliola D, ANRS AC11 Resistance Study Group: Increasing prevalence of transmitted drug resistance mutations and non-B subtype circulation in antiretroviralnaive chronically HIV-infected patients from 2001 to 2006/2007 in France. J Antimicrob Chemother 2010;65:2620-2627.
7. Jain V, Liegler T, Vittinghoff E, Hartogensis W, Bacchetti P, Poole L, Loeb L, Pilcher C-grave, Grant RM, Deeks SG, Hecht FM: Transmitted drug resistance in persons with acute/early HIV-1 in San Francisco, 2002-2009. PLoS One 2010;5:e15510
8. Riva C, Lai A, Caramma I, Corvasce S, Violin M, Dehò L, Prati F, Rossi C, Colombo MC, Capetti A, Franzetti M, Rossini V, Tambussi G, Ciccozzi M, Suligoi B, Mussini C, Rezza G, Balotta C: Transmitted HIV type 1 drug resistance and non-B subtypes prevalence among seroconverters and newly diagnosed patients from 1992 to 2005 in Italy. AI-graveS Res Hum Retroviruses 2010;26:41-49.
9. Vercauteren J, Derdelinckx I, Sasse A, Bogaert M, Ceunen H, De Roo A, De Wit S, Deforche K, Echahidi F, Fransen K, Goffard JC, Goubau P, Goudeseune E, Yombi JC, Lacor P, Liesnard C, Moutschen M, Pierard D, Rens R, Schrooten Y, Vaira D, van den Heuvel A, van der Gucht B, van Ranst M, van Wijngaerden E, Vandercam B, Vekemans M, Verhofstede C, Clumeck N, Vandamme AM, van Laethem K: Prevalence and epidemiology of HIV type 1 drug resistance among newly diagnosed therapy-naive patients in Belgium from 2003 to 2006. AI-graveS Res Hum Retroviruses 2008;24:355-362.
10. Wheeler WH, Ziebell RA, Zabina H, Pieniazek D, Prejean J, Bodnar UR, Mahle KC, Heneine W, Johnson JA, Hall HI, Variant, Atypical, and Resistant HIV Surveillance Group: Prevalence of transmitted drug resistance associated mutations and HIV-1 subtypes in new HIV-1 diagnoses, U. S.-2006. AI-graveS 2010;24:1203-1212.
11. Yerly S, von Wyl V, Ledergerber B, Böni J, Schüpbach J, Bürgisser P, Klimkait T, Rickenbach M, Kaiser L, Günthard HF, Perrin L, Swiss HIV Cohort Study: Transmission of HIV-1 drug resistance in Switzerland: a 10-year molecular epidemiology survey. AI-graveS 2007;21:2223-2229.
12. Bansi L, Geretti AM, Dunn D, Hill T, Green H, Fearnhill E, Gazzard B, Nelson M, Porter K, Phillips A, Sabin C, UK Collaborative Group on HIV Drug Resistance and UK Collaborative HIV Cohort (CHIC) Study: Impact of transmitted drug-resistance on treatment selection and outcome of firstline highly active antiretroviral therapy (HAART). J Acquir Immune Defic Syndr 2010;53:633-639.
13. Balduin M, Oette M, Däumer MP, Hoffmann D, Pfister HJ, Kaiser R: Prevalence of minor variants of HIV strains at reverse transcriptase position 103 in therapy-naive patients and their impact on the virological failure. J Clin Virol 2009;45:34-38.
14. Geretti AM, Fox ZV, Booth CL, Smith CJ, Phillips AN, Johnson M, Li JF, Heneine W, Johnson JA: Low-frequency K103N strengthens the impact of transmitted drug resistance on virologic responses to first-line efavirenz or nevirapine-based highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2009;52:569-573.
15. Ghosn J, Pellegrin I, Goujard C, Deveau C, Viard JP, Galimand J, Harzic M, Tamalet C, Meyer L, Rouzioux C, Chaix ML, French PRIMO Cohort Study Group (ANRS CO 06): HIV-1 resistant strains acquired at the time of primary infection massively fuel the cellular reservoir and persist for lengthy periods of time. AI-graveS 2006;20:159-170.
16. Little SJ, Holte S, Routy JP, Daar ES, Markowitz M, Collier AC, Koup RA, Mellors JW, Connick E, Conway B, Kilby M, Wang L, Whitcomb JM, Hellmann NS, Richman D-grave: Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002;347:385-394.
17. Violin M, Cozzi-Lepri A, Velleca R, Vincenti A, D'Elia S, Chiodo F, Ghinelli F, Bertoli A, d'Arminio Monforte A, Perno CF, Moroni M, Balotta C: Risk of failure in patients with 215 HIV-1 revertants starting their first thymidine analog-containing highly active antiretroviral therapy. AI-graveS 2004;18:227-235.
18. Riddler SA, Haubrich R, Di Rienzo AG, Peeples L, Powderly WG, Klingman KL, Garren KW, George T, Rooney JF, Brizz B, Lalloo UG, Murphy RL, Swindells S, Havlir D, Mellors JW, AI-graveS Clinical Trials Group Study A5142 Team: Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 2008;358:2095-2106.
19. Oette M, Kaiser R, Däumer M, Akbari D, Fätkenheuer G, Rockstroh JK, Stechel J, Rieke A, Mauss S, Schmalöer D, Göbels K, Vogt C, Wettstein M, Häussinger D: Primary drug-resistance in HIV-positive patients on initiation of first-line antiretroviral therapy in Germany. Eur J Med Res 2004;9:273-278.
20. Oette M, Kaiser R, Däumer M, Petch R, Fätkenheuer G, Carls H, Rockstroh JK, Schmalöer D, Stechel J, Feldt T, Pfister H, Häussinger D: Primary HIV drug resistance and efficacy of first-line antiretroviral therapy guided by resistance testing. J Acquir Immune Defic Syndr 2006;41:573-581.
21. Beerenwinkel N, Däumer M, Oette M, Korn K, Hoffmann D, Kaiser R, Lengauer T, Selbig J, Walter H: Geno2pheno: estimating phenotypic drug resistance from HIV-1 genotypes. Nucleic Acids Res 2003;31:3850-3855.
22. Bennett DE, Camacho RJ, Otelea D, Kuritzkes DR, Fleury H, Kiuchi M, Heneine W, Kantor R, Jordan MR, Schapiro JM, Vandamme AM, Sandstrom P, Boucher CA, van de Vijver D, Rhee SY, Liu TF, Pillay D, Shafer RW: Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance:2009 update. PLoS One 2009;4:e4724.
23. Yebra G, Holguin A: Epidemiology of drugresistant HIV-1 transmission in naive patients in Spain. Med Clin (Barc) 2010;135:561-567.
24. Recordon-Pinson P, Anies G, Bruyand M, Neau D, Morlat P, Pellegrin JL, Groppi A, Thiébaut R, Dabis F, Fleury H, Masquelier B, ANRS CO3 Aquitaine Cohort: HIV type-1 transmission dynamics in recent seroconverters: relationship with transmission of drug resistance and viral diversity. Antivir Ther 2009;14:551-556.
25. Chan PA, Tashima K, Cartwright CP, Gillani FS, Mintz O, Zeller K, Kantor R: Transmitted drug resistance and molecular epidemiology in antiretroviral naive HIV type 1-infected patients in Rhode Island. AI-graveS Res Hum Retroviruses 2011;27:275-281.
26. Vercauteren J, Wensing AM, van de Vijver DA, Albert J, Balotta C, Hamouda O, Kücherer C, Struck D, Schmit JC, Asjö B, Bruckova M, Camacho RJ, Clotet B, Coughlan S, Grossman Z, Horban A, Korn K, Kostrikis L, Nielsen C, Paraskevis D, Poljak M, Puchhammer-Stöckl E, Riva C, Ruiz L, Salminen M, Schuurman R, Sonnerborg A, Stanekova D, Stanojevic M, Vandamme AM, Boucher CA: Transmission of drug-resistant HIV-1 is stabilizing in Europe. J Infect Dis 2009;200:1503-1508.
27. Di Giambenedetto S, Bracciale L, Colafigli M, Cattani P, Pinnetti C, Bacarelli A, Prosperi M, Fadda G, Cauda R, De Luca A: Declining prevalence of HIV-1 drug resistance in treatment-failing patients: a clinical cohort study. Antivir Ther 2007;12:835-839.
28. Vercauteren J, Deforche K, Theys K, Debruyne M, Duque LM, Peres S, Carvalho AP, Mansinho K, Vandamme AM, Camacho R: The incidence of multidrug and full class resistance in HIV-1 infected patients is decreasing over time (2001-2006) in Portugal. Retrovirology 2008;5:12.
29. von Wyl V, Yerly S, Bürgisser P, Klimkait T, Battegay M, Bernasconi E, Cavassini M, Furrer H, Hirschel B, Vernazza PL, Francioli P, Bonhoeffer S, Ledergerber B, Günthard HF, Swiss HIV Cohort Study: Long-term trends of HIV type 1 drug resistance prevalence among antiretroviral treatment-experienced patients in Switzerland. Clin Infect Dis 2009;48:979-987.
30. Taylor S, Jayasuriya A, Smit E: Using HIV resistance tests in clinical practice. J Antimicrob Chemother 2009;64:218-222.
31. Little SJ, Frost S-grave, Wong JK, Smith DM, Pond SL, Ignacio CC, Parkin NT, Petropoulos CJ, Richman D-grave: Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infection. J Virol 2008;82:5510-5518.
32. Hue S, Gifford RJ, Dunn D, Fernhill E, Pillay D, UK Collaborative Group on HIV Drug Resistance: Demonstration of sustained drug-resistant human immunodeficiency virus type 1 lineages circulating among treatment-naive individuals. J Virol 2009;83:2645-2654.